SillaGen and Shinshin Pharmaceutical Sign Joint Sales Agreement for Prescription Drug Infusions

SillaGen to Supply Infusion Products to Shinshin Pharmaceutical

SillaGen and Shinshin Pharmaceutical have signed a joint sales agreement to supply and act as sales agents for prescription drug infusions (ETC). Sangkyu Han, CEO of SillaGen, and Byungki Lee, CEO of Shinshin Pharmaceutical, finalized the agreement on June 8 at the Shinshin Pharmaceutical headquarters in Magok-dong, Gangseo-gu, Seoul, by signing the contract, confirming the two companies' collaboration in joint sales.

SillaGen will supply four types of prescription drug infusion products to Shinshin Pharmaceutical, and Shinshin Pharmaceutical plans to begin sales to new clients in addition to SillaGen’s existing customers. The contract period is up to five years and can be extended by mutual agreement between the two parties.

Sangkyu Han, CEO of Sillajen (left), and Byunggi Lee, CEO of Shinshin Pharmaceutical (right), are taking a commemorative photo after signing a joint sales agreement for prescription infusion products at the Shinshin Pharmaceutical headquarters in Magok-dong, Gangseo-gu, Seoul on the 8th. Sillajen

Last year, SillaGen acquired Woosung Pharmaceutical (now its pharmaceutical business division), a company specializing in infusion products, and has since continued to pursue revenue growth and new drug development. In particular, its main product, New Aminophen Premix Injection, is experiencing rapid growth. As the only pediatric indication drug of its kind in Korea, it is showing steady demand not only from its main clients—tertiary hospitals—but also from local hospitals.

Shinshin Pharmaceutical, established in 1959, is a pharmaceutical company specializing in pain care, holding a leading position in the field of topical agents, especially patches. Recently, based on its high growth rate, the company has been proactively expanding its lineup of prescription drugs beyond its existing topical agent market. Its strategic interests align with SillaGen’s efforts to expand its market, leading to the decisive execution of this joint sales agreement.

Beyond this joint sales contract, both companies have also reached a consensus on the potential for broader collaboration, such as developing new drugs utilizing Shinshin Pharmaceutical’s unique patch technology and pursuing additional partnerships on future products developed by SillaGen.

A SillaGen representative stated, “We will do our best to supply drugs with excellent efficacy and quality to Shinshin Pharmaceutical, a renowned and long-established domestic company,” adding, “We expect to see high growth rates if we secure a large number of new clients in addition to existing ones.”

A Shinshin Pharmaceutical representative commented, “We are very pleased to collaborate with SillaGen, which has shown remarkable growth in the infusion sector,” and added, “We will do our utmost to ensure the success of this partnership, leveraging our extensive sales experience and infrastructure.”

This content was produced with the assistance of AI translation services.